Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency
February 19, 2019 08:27 ET
|
Cerecor, Inc.
ROCKVILLE, Md., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
Cerecor Announces CERC-301 Granted U.S. Patent
February 15, 2019 06:30 ET
|
Cerecor, Inc.
ROCKVILLE, Md., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and...
Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland
January 28, 2019 06:30 ET
|
Cerecor, Inc.
ROCKVILLE, Md., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and...
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
January 22, 2019 06:30 ET
|
Cerecor, Inc.
ROCKVILLE, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation
January 16, 2019 06:30 ET
|
Cerecor, Inc.
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and...
Cerecor Reports Third Quarter 2018 Results
November 13, 2018 07:00 ET
|
Cerecor, Inc.
BALTIMORE, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and...
Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation
October 31, 2018 16:00 ET
|
Cerecor, Inc.
BALTIMORE, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and...
Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism
October 30, 2018 16:00 ET
|
Cerecor, Inc.
BALTIMORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and...
Cerecor to Participate in Upcoming Healthcare Conferences
September 26, 2018 13:00 ET
|
Cerecor, Inc.
BALTIMORE, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today...
Cerecor to Acquire Ichorion Therapeutics
September 25, 2018 06:30 ET
|
Cerecor, Inc.
Transaction worth approximately $26.6 Million in Stock Plus Potential Milestones Accelerates Cerecor’s Transformation Strategy; Strengthens Rare Disease Pipeline and Expands Pediatric Portfolio ...